

EXHIBIT L

Exhibit L to the Declaration

Document Title/ECF No.	Basis for Sealing	Clearly Defined and Serious Injury that Would Result if the Relief is Not Granted	Why a Less Restrictive Alternative to the Relief Sought is Not Available	Any Prior Order Sealing the Same Materials in the Pending Action	Party in Opposition to Sealing, if any, and Basis
Letter dated February 20, 2024 [ECF No. 280]	Letter contains reference to data analyzed by SaveOn for strategic purposes, comprising proprietary business information, <i>see</i> ECF No. 280 at Ex. 12.	If relief is not granted, SaveOn would be at a competitive disadvantage should its proprietary non-public business information and strategy be disclosed to competitors and other market participants.	A redacted, public version of the letter is being filed. It is believed that no less restrictive alternative is available to prevent the disclosure of SaveOn's proprietary business information.	No	No objection
Exhibit 12 to letter dated February 20, 2024 [ECF No. 280]	Exhibit 12 is a SaveOn presentation analyzing patient and medication data, comprising proprietary business information. <i>See</i> ECF No. 280 at Ex. 12.	If relief is not granted, SaveOn would be at a competitive disadvantage should its proprietary non-public business information be disclosed to competitors and other market participants.	It is believed that no less restrictive alternative is available to prevent the disclosure of SaveOn's proprietary business information.	No	No objection
Letter dated March 1, 2024 [ECF No. 280]	Letter contains reference to data analyzed by SaveOn for strategic purposes, comprising proprietary business information, <i>see</i> ECF No. 280 at Ex. 2-4.	If relief is not granted, SaveOn would be at a competitive disadvantage should its proprietary non-public business information and strategy	A redacted, public version of the letter is being filed. It is believed that no less restrictive alternative is available to prevent the disclosure of	No	No objection

		be disclosed to competitors and other market participants.	SaveOn's proprietary business information.		
Exhibit 2 to letter dated March 1, 2024 [ECF No. 280]	Exhibit 2 is an internal email chain between SaveOn employees discussing patient and medication data, comprising proprietary business information. <i>See</i> ECF No. 280 at Ex. 2.	If relief is not granted, SaveOn would be at a competitive disadvantage should its proprietary non-public business information be disclosed to competitors and other market participants.	It is believed that no less restrictive alternative is available to prevent the disclosure of SaveOn's proprietary business information.	No	No objection
Exhibit 3 to letter dated March 1, 2024 [ECF No. 280]	Exhibit 3 is an email chain between Express Scripts and Accredo employees discussing patient and medication data in relation to SaveOn, comprising proprietary business information. <i>See</i> ECF No. 280 at Ex. 3.	If relief is not granted, SaveOn would be at a competitive disadvantage should its proprietary non-public business information be disclosed to competitors and other market participants.	It is believed that no less restrictive alternative is available to prevent the disclosure of SaveOn's proprietary business information.	No	No objection
Exhibit 4 to letter dated March 1, 2024 [ECF No. 280]	Exhibit 4 is an email chain between Express Scripts and Accredo employees discussing patient and medication data in relation to SaveOn, comprising proprietary business information. <i>See</i> ECF No. 280 at Ex. 4.	If relief is not granted, SaveOn would be at a competitive disadvantage should its proprietary non-public business information be disclosed to competitors and other market participants.	It is believed that no less restrictive alternative is available to prevent the disclosure of SaveOn's proprietary business information.	No	No objection

Letter dated March 11, 2024 [ECF No. 280]	Letter references letter dated March 1, 2024, <i>see</i> ECF No. 280, which references SaveOn's patient and medication data, comprising proprietary business information. <i>See</i> ECF No. 280.	If relief is not granted, SaveOn would be at a competitive disadvantage should its proprietary non-public business information and strategy be disclosed to competitors and other market participants.	A redacted, public version of the letter is being filed. It is believed that no less restrictive alternative is available to prevent the disclosure of SaveOn's proprietary business information.	Yes, <i>see</i> ECF No. 280 at Letter Dated March 1, 2024.	No objection
---	---	--	---	--	--------------